

11-09-2000

16

CLAIMS

- 1 A preparation for restoring bone in the body of humans or  
5 animals in connection with an existing structure, a bone implant or  
some other prosthetic construction, the preparation being intended to  
be applied in the position in connection with, for instance, a bone  
implant or some other prosthetic construction where there is a lack  
10 of sufficient bone volume, or where the quality of the bone is too  
poor, or to allow a load-carrying function, said preparation being  
an easily handleable, controllable and decomposable carrier  
preparation of calcium phosphate granules or a biological organic  
component of a biopolymer and/or lipid type characterised  
15 in that the preparation at its application has a mouldable  
consistency by admixed water or some other water-based liquid, such  
as body fluid.
2. A preparation as claimed in claim 1, characterised  
20 in that the lipid consists of a mixture of esterified glycerol and  
phospholipid.
3. A preparation as claimed in claim 2, characterised  
in that the esterified glycerol consists of di- and triglyceride.
- 25 4. A preparation as claimed in claim 2, characterised  
in that the esterified glycerol is a diester.
5. A preparation as claimed in claim 2, characterised  
in that the esterified glycerol is a triester.
- 30 6. A preparation as claimed in claim 1, characterised  
in that the lipid consists of a mixture of phospholipids.
7. A preparation as claimed in claim 6, characterised  
35 in that the phospholipid is a sphingomyelin.

AMENDED SHEET

11-09-2000

17

8. A preparation as claimed in claim 6, characterised  
in that the phospholipid is a phosphatidyl choline.
9. A preparation as claimed in claim 1, characterised  
5 in that the lipid is prepared from a vegetable oil or egg yolk.
10. A preparation as claimed in any one of the preceding claims,  
characterised in that the lipid consists of at least one  
phospholipid and water or some other water-based liquid as carrier.
- 10 11. A preparation as claimed in claim 10, characterised  
in that the lipid is in a lamellar floating crystalline phase.
12. A preparation as claimed in claim 10, characterised  
15 in that the weight ratio between lipid and water or some other water-  
based liquid is in the order of 1:2 to 10:1, preferably 3:2 to 4:1.
13. A preparation as claimed in claim 1, characterised  
in that the biopolymer contains a glycoaminoglycan, for example  
20 hyaluronic acid.
14. A preparation as claimed in claim 13, characterised  
in that it consists of a free-flowing mixture of sodium hyaluronic  
acid and calcium phosphate granules which can be packed and then  
25 rehydrated in connection with use.
15. A preparation as claimed in claim 1, characterised  
in that the calcium phosphate granules have a Ca/P ratio which is  
between 1 and 2.
- 30 16. A preparation as claimed in claim 15, characterised  
in that the calcium phosphate contains hydroxyapatite of the form  
 $\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$ .
- 35 17. A preparation as claimed in claim 15, characterised  
in that the calcium phosphate contains dicalcium phosphate dihydrate,  
octacalcium phosphate, tricalcium phosphate and/or hydroxyapatite.

AMENDED SHEET

18. A preparation as claimed in claim 15, characterised  
in that the calcium phosphate contains magnesium, fluorine or  
carbonate ions.

5

19. A preparation as claimed in claim 15, characterised  
in that the calcium phosphate granules have a diameter in the order  
of 0.05 mm to 5 mm.

10

20. A preparation as claimed in claim 15, characterised  
in that the calcium phosphate granules have a porosity of 0-80%.

15

21. A preparation as claimed in any one of the preceding claims,  
characterised in that the weight ratio between the  
calcium phosphate granules and the lipid is in the order of 70:15 to  
60:40.

20

22. A preparation as claimed in any one of the preceding claims,  
characterised in that it contains tissue-promoting  
factors and/or factors which inhibit decomposition of tissue, for  
example a growth factor, such as BMP and TGF beta or parts thereof.

25

23. A preparation as claimed in claims 1, 14 and 22,  
characterised in that the tissue-promoting factor is  
added wholly or partially.

add  
a1  
7addB1